Joseph Emile Eid
Executive VP of Research & Development and Chief Medical OfficerDr. Joseph Emile Eid, also known as Joe, M.D., is Chief Medical Officer of Luminary Therapeutics Inc. from December 2022. He joined and served as President of Research and Development of DRAGONFLY Therapeutics, Inc. since February 2023. Dr. Eid brings deep immunotherapy clinical development experience including as team leader at Merck in the Pembrolizumab (anti-PD-1 antibody) first in human trial leading to registration of KEYTRUDA. His career in clinical development, he has contributed to a number of leading therapies from early clinical stages through approval. He served as Senior Vice President and Head of Global Medical Affairs at BMS, as well as a leader in Oncology Clinical Research at Roche Pharmacuticals. He is responsible for all aspects of clinical development and research at Dragonfly. He served as Non-Executive Director CelLBxHealth plc (formerly known as ANGLE plc) since January 19, 2023 until January 31, 2026. He was Senior Vice President and Head of Global Medical Affairs at Bristol-Myers Squibb Company since 2019. He served as Chief Medical Officer and Head of Global Drug Development for Princeton New Jersey based Luzsana Biotechnology. He was Head of Global Medical at Bristol-Myers Squibb Company since 2017 until 2019 and was its Vice President of Head of Oncology Global Medical Affairs and Merck at Bristol-Myers Squibb Company since 2014 to 2017. As Head of Global Medical Affairs. Dr. Joseph Eid leads the company?s efforts to communicate the safe and appropriate utilization of its medicines to the medical community and gather insights on medical practices and patient needs from stakeholders. Internally, Joe?s organization also plays a critical role as the bridge between the drug development and commercial organizations. Before joining BMS in 2017, Joe spent years at Merck, served as Head of Oncology Global Medical Affairs. Previously, he served in Merck Research Labs as Team Leader for the anti-PD-1 antibody program, where he managed the first-in-human trials and set the strategy leading to registration. Prior to joining Merck, he was Clinical Team Leader and Science Team Leader in Oncology Clinical Research at Hoffmann-La Roche AG. Dr. Eid holds a medical degree from St. Joseph University School of Medicine in Beirut, Lebanon and is Board certified in Medical Oncology, Hematology and Internal Medicine. He completed his fellowship in Hematology and Medical Oncology at Rutgers-Robert Wood Johnson Medical School (RWJMS) and served on the RWJMS faculty as Assistant Professor of Medicine in the departments of Medicine and Pathology and Laboratory Medicine. Dr. Eid is Executive Vice President, Research & Development of Geron Corporation from November 11, 2024 and also serves as it's Chief Medical Officer from October 2025.
Positions
- Company NameGeron CorporationStock CodeGERNPositionExecutive VP of Research & Development and Chief Medical OfficerColleagues
- HSHarout SemerjianCEO, President & Director
- EGElizabeth G. O'FarrellIndependent Chairman of the Board
- MJMichelle J. RobertsonEVP, CFO, Treasurer and Principal Financial & Accounting Officer
- AEAhmed ElNawawiExecutive VP & Chief Commercial Officer
- STShanthakumar TyavanagimattSenior VP & Chief Technical Officer
- SMSusan M. MolineauxIndependent Director
- DCDawn Carter BirIndependent Director
- RJRobert Jay SpiegelIndependent Director
